• Home
  • About OliX

About OliX

History

2021

  • Feb.

    Receives KNDA (Korea New Drug Award)

  • Jan.

    Establishes subsidiary, mCureX Therapeutics, Inc.

2020

  • Dec.

    Certified as Family–friendly and Innovative pharmaceutical company

  • Oct.

    [OLX301A · OLX301D] Expanded Out-Licensing Agreement
    with Théa (Worldwide excl. Asia- Pacific)

    [OLX101A] IND Phase 2 study permitted (US)

  • Jun.

    R&D(GalNAc-siRNA) Supply contract with
    global pharmaceutical company

  • Mar.

    The GalNAc Technology from AM Chemicals is instituted

2019

  • Nov.

    [OLX101A] Phase 1 clinical trial for OLX10010
    (candidate substance for the treatment
    of hypertrophic scarring) is completed in the UK

  • Apr.

    [OLX201A] Candidate substance for the treatment
    of Idiopathic Pulmonary Fibrosis is patented in the US

  • Mar.

    [OLX301A] Out-Licensing Agreement with Théa Open Innovation
    (EU, MEA, Africa)

  • Feb.

    [OLX103] Candidate substance for the treatment
    of Atopic Dermatitis is patented in the US

    OliX San Diego R&D Lab is established

2018

  • Nov.

    Compound for increasing siRNA and RNA interference
    effects is patented in Korea

    [OLX101A] Candidate substance for the treatment
    of hypertrophic scarring is patented in Europe

    [OLX101A] Phase 2 clinical trial is approved in Korea
    for candidate substance for the treatment of hypertrophic scarring

  • Oct.

    Phase 1 study of OLX10010, a potential treatment
    for hypertrophic scar using a self-delivering RNAi compound,
    is selected as a KOREA Drug Development
    Fund project OliX US Inc. is established

  • Jul.

    [OLX301A] Candidate substance for the treatment
    for age-related macular degeneration is patented in the US

    OliX gets listed on the KOSDAQ

  • May.

    [OLX101A] CTA approves phase 1 clinical trial
    for the treatment of hypertrophic scarring
    in the UK (MHRtrial for OLX10010 (candidate A)

    [OLX101A] Phase 1 clinical trial
    for OLX10010 (candidate substance for the treatment of
    hypertrophic scarring) is completed in Korea

2017

  • Oct.

    OliX passes the technology evaluation (A, A) for IPO

  • Jun.

    The Sr. VP receives the KFDA Award

  • May.

    Asymmetric lasiRNA platform is patented in the US

  • Feb.

    The Nucleic Acid Eye Center is opened

  • Jan.

    OliX moves its company to Suwon
    [OLX101A] Phase 1 clinical trial is approved
    in Korea forcandidate substance for
    the treatment of hypertrophic scarring

2016

  • Dec.

    The CEO receives the Minister of Health & Welfare Award

  • Jul.

    [OLX101A] Hypertrophic scarring therapeutics data
    in Journal of Investigative Dermatology is published

  • Apr.

    Series B funding is completed

  • Mar.

    [OLX102] (a skin whitening substance) gets listed on ICID

2015

  • Jul.

    OliX gets certified as Technology Innovative Small
    to Medium Enterprise (INNO-BIZ)

  • Jun.

    Hugel Inc. makes a strategic investment in OliX

  • Apr.

    'Development of RNA interference based atopic dermatitis
    treatment' is selected as a Technology Development Support Project
    (KOREA Small and Medium Business Administration)

2014

  • Nov.

    'Pre-clinical and clinical study of anti-scarring therapeutics BMT101
    self-delivering RNAi molecule.' is selected
    as a KOREA Drug Development Fund project

  • Oct.

    The company name is changed to OliX, Inc.

  • Sep.

    'Therapeutics development for Idiopathic Pulmonary
    Fibrosis using BMT101 a pre-validated oligonucleotide drug
    inhibiting fibrosis' is selected as a Korea-Singapore
    R&D project (Ministry of Health and Welfare)

  • Aug.

    Series A funding is completed

2013

  • Nov.

    [OLX101A] OliX makes a Collaboration and License
    Agreement with Hugel Inc. for the treatment of hypertrophic scarring

  • May.

    A patent application for cp-asiRNA platform is filed

  • Feb.

    Angel investment is raised

2012

  • Nov.

    OliX moves to Gasan Digital Complex

  • May.

    Patent application for cp-asiRNA platform is filed

2011

  • Dec.

    cp-asiRNA platform development is initiated

  • Oct.

    Company affiliated research center is certified

  • Jun.

    An exclusive license for asymmetric lasiRNA is obtained

2010

  • Sep.

    OliX gets certified as a venture company (Kibo Technology Fund)

  • Mar.

    An exclusive license for asymmetric siRNA is obtained

  • Feb.

    BMT, Inc. is established

LOGO DESIGN

  • 2010.02 ~ 2012.10

  • 2012.11 ~ 2014.09

  • 2014.10 ~ Present